Daily FNArena News - Small Caps

In the wake of Telix Pharmaceuticals’ non-IPO on the Nasdaq, FNArena shines a light on the company’s fortunes and that of Australian biotech and cancer research generally

Analysts highlight structural tailwinds for Ventia Services and margin protection from contract mix and flexible costs

Following its near-death experience last year, BNPL provider Zip Co has made a strong comeback. Evans & Partners has initiated coverage

Superloop management has raised FY24 earnings guidance and confirmed the Origin Energy customer transition is on track. Analysts see additional growth opportunities

The New Criterion’s Tim Boreham explains the how and why behind Radiopharm Theranostics’ latest capital raising

Brokers highlight deregulation and scale benefits from the potential merger of Integral Diagnostics and Capitol Health 

Deterra Royalties is looking to diversify away from iron ore royalties and provide for growth, in lithium in particular. The trade-off is a much-reduced dividend yield

Codan has surprised with the performance of its metal detection business, but it is the company’s communications business that has brokers excited

The next twelve months could be exciting for Dengue fever solutions seeker Island Therapeutics, the New Criterion’s Tim Boreham reports

Alternative asset manager Regal Partners has enjoyed impressive organic and inorganic funds under management growth in recent years and brokers see more ahead